Cancer Genetics, Inc. to Present at the 2nd Annual Disruptive Growth & Healthcare Conference
Feb 13, 2017 12:30 pm UTC| Business
RUTHERFORD, N.J., Feb. 13, 2017 -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will be presenting at the...
Feb 13, 2017 12:05 pm UTC| Business
VY-SOD101 Selected Based on Robust Delivery and Knock-Down of Toxic SOD1 in Preclinical Models Program On Track for IND filing during 4Q:17 CAMBRIDGE, Mass., Feb. 13, 2017 -- Voyager Therapeutics, Inc....
Evogene Fourth Quarter and Full Year 2016 Earnings Announcement Schedule
Feb 13, 2017 12:02 pm UTC| Business
REHOVOT, Israel, Feb. 13, 2017 -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity, announced today that it will release its financial results for the...
Nokia lays key 5G foundation with world's first 5GTF connection
Feb 13, 2017 12:02 pm UTC| Business
Press Release Telecom industry's first connection made conforming to 5GTF interface the industry-agreed specification for 'pre-standard' 5G applications, marking major milestone towards 3GPP NR Trial done in Oulu,...
Nokia lays key 5G foundation with world's first 5GTF connection
Feb 13, 2017 12:02 pm UTC| Business
Press Release Telecom industry's first connection made conforming to 5GTF interface the industry-agreed specification for 'pre-standard' 5G applications, marking major milestone towards 3GPP NR Trial done in Oulu,...
Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook
Feb 13, 2017 12:02 pm UTC| Business
HAIFA, Israel, Feb. 13, 2017 -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today reported financial update and corporate and clinical developments...
Pluristem Reports Second Quarter Fiscal 2017 Highlights & Provides Calendar 2017 Outlook
Feb 13, 2017 12:02 pm UTC| Business
HAIFA, Israel, Feb. 13, 2017 -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today reported financial update and corporate and clinical developments...